Prevalence Of Nephropathy In Multiple Myeloma Patients: An
Experience Of Single Center
BÜLENT SAVUT, İSMAİL BALOĞLU, HALİL ZEKİ TONBUL, NEDİM YILMAZ SELÇUK, KÜLTİGİN TÜRKMEN
- Year : 2017
- Vol : 33
- Issue : 3
- Page :
54-57
Multiple myelom (MM) is a plasma cell malignancy and is
characterized by anemia, recurrent infections, serum and/or urine
monoclonal protein, osteolytic bone lesions, hypercalcemia and
renal failure. The prevalence of nephropathy varies between 20 and
50% in MM. In this study, the prevalence of nephropathy and related
factors were aimed to investigate in MM patients who admitted to the
Hematology and Nephrology clinics of Meram Faculty of Medicine,
Necmettin Erbakan University. A total of 104 MM patients (F/M: 55/49)
were retrospectively examined who were administered in the last five
years. The mean follow up duration was 29 months. The mean age
was 64±10.6 years. During the follow-up period, 30.8% of our patients
died and 58% were still alive. The fate of the 10.6% of the patients
could not be learned. Patients with serum creatinine ≥2 mg/dL were
considered as patients with nephropathy. The vincristine-adriamycindexamethasone
or melfelan-methylprednisolone (for patients >65
years) were administered as initial therapy. Statistical analysis was
performed with SPSS 15.0. Renal involvements were observed in 33
patients (31.7%). Hyperuricemia (p=0.002), hypercalcemia (p=0.037),
hypovolemia (p<0.001) and oliguria (p<0.001) were found to be
higher in patients with creatinine ≥2 mg/dL. In 31 patients (29.8%),
hemodialysis (HD) treatment was required, 19 of these (61.2% of HD
patients, 18.2% of all patients) were treated with HD permanently.
Mortality rates were found as %42 in patients with nephropathy
and %25.3 without nephropathy (p=0.034). Renal failure is a poor
prognostic marker in multiple myeloma. In this study one-third of MM
patients had nephropathy requiring HD. Although renal insufficiency
is mainly due to monoclonal light chain nephropathy, reversible
causes such as hypovolaemia should be carefully evaluated. We
think that particular attention should be paid to this group because of
the increased risk of mortality.
Cite this Article As :
Download Citation: Endnote/Zotero/Mendeley (RIS) RIS File
Download Citation: BibTeX BibTeX File
Description :
None of the authors, any product mentioned in this article,
does not have a material interest in the device or drug. Research,
not supported by any external organization.
grant full access to the primary data and, if requested by the magazine
they agree to allow the examination of data.
Prevalence Of Nephropathy In Multiple Myeloma Patients: An
Experience Of Single Center
2017,
Vol.
33
(3)
Received : 13.02.2017,
Accepted : 13.02.2017,
Published Online : 13.08.2018
Selçuk Tıp Dergisi
ISSN:1017-6616;
E-ISSN:2149-8059;